Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2022-10-27 Major Shareholding Noti…
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
IDEAYA BIOSCIENCES, INC.
Major Shareholding Notification
2022-10-27 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content describes an underwriting agreement for a stock offering, including details about the shares issued, pricing, underwriters, and closing of the offering. It also references exhibits related to the underwriting agreement and legal opinions. This is clearly an update on the company's capital raising activity and financing. It is not a full financial report, earnings release, or management discussion, but rather a specific announcement about financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-09-19 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by IDEAYA Biosciences, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It clearly relates to a financing activity and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence level.
2022-09-15 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by IDEAYA Biosciences, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The presence of terms like 'prospectus supplement', 'common stock offering', 'underwriting discounts', and references to SEC registration and filing rules clearly indicate this is a capital raising document. It is not a financial report, earnings release, or management discussion, but rather a detailed offering prospectus supplement related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-09-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on clinical trial updates and other business developments rather than financial results or detailed financial statements. It does not contain comprehensive financial data or management discussion typical of Annual Reports (10-K) or Interim Reports (IR). It is not an earnings release (ER) since it lacks key financial highlights. The document is not a proxy statement, governance report, or management change announcement. It is a regulatory filing reporting clinical data updates and other corporate events. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (13,330 characters) and detailed clinical data support that it is a substantive regulatory announcement rather than a brief report publication announcement (RPA).
2022-09-14 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.